Silodosin Capsule
Product Images NDC 33342-384

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Silodosin (NDC 33342-384). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30s (Silodosin 4 mg 30s)

Silodosin Capsules 4 mg oral dose, packaging label showing product name, strength, and dosage form. Contains 30 capsules. Labeler is Macleods Pharmaceuticals Limited with manufacturing by Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. Addresses for Princeton, NJ, USA and Daman, India are noted. Includes usage instructions, storage conditions, barcode, and regulatory information.*

FDA Label Image

Silodosin 4 mg 90s

Silodosin Capsules 4 mg label from Macleods Pharmaceuticals Limited. The label states the product contains 90 capsules, each with 4 mg silodosin. It includes storage information, usual dosage instructions, and manufacturing details for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd., India. The label features barcodes and a caution to keep out of reach of children.*

FDA Label Image

30s (Silodosin 8 mg 30s)

Silodosin Capsules 8 mg label from Macleods Pharmaceuticals Limited. The oral capsule package contains 30 capsules and is manufactured for Macleods Pharma USA, Inc. Dosage instructions and storage conditions are included on the label, which also features barcodes and the NDC 33342-385-07.*

FDA Label Image

90s (Silodosin 8 mg 90s)

Silodosin Capsules 8 mg oral capsules packaging label by Macleods Pharmaceuticals Limited. The label states each capsule contains 8 mg Silodosin and the package contains 90 capsules. Storage instructions include keeping between 20° to 25°C with permitted excursions. It is manufactured for Macleods Pharma USA, Inc. in Princeton, NJ, and by Macleods Pharmaceuticals Ltd. in Daman, India. The label also includes a caution to keep out of reach of children.*

FDA Label Image

123 (Silodosin Cart 4mg)

Silodosin Capsules 4 mg oral unit-dose packaging label by Macleods Pharmaceuticals Limited. The label includes dosage strength highlighted in green, manufacturer details, barcode, package size of 100 capsules (10 x 10 unit-dose), and storage instructions. The label states Rx only and specifies the usual dosage as one capsule daily with a meal.*

FDA Label Image

444 (Silodosin Cart 8mg)

Silodosin Capsules 8 mg oral capsules packaging label from Macleods Pharmaceuticals Limited. The label includes the product name with the strength prominently displayed, manufacturer information listing Macleods Pharma USA Inc. and Macleods Pharmaceuticals Ltd., a barcode, and storage instructions. The package contains 100 capsules in a 10 x 10 unit-dose configuration and is labeled for prescription use only.*

FDA Label Image

333 (Silodosin Fig 02)

A line graph depicting change from baseline in IPSS total score over time (days) comparing Silodosin 8 mg and placebo. The y-axis shows change in IPSS score, and the x-axis shows days from baseline including 3.5, 7, 14, 28, and 84. The Silodosin 8 mg group shows a greater decrease in IPSS score over time compared to placebo.*

FDA Label Image

222 (Silodosin Fig 1)

A line graph depicting silodosin concentration (ng/mL) in the blood over time (hours). The concentration peaks around 4 hours and then declines, with error bars indicating variability at each time point, extending to 24 hours.*

FDA Label Image

444 (Silodosin Fig 3)

A line graph comparing the change from baseline in IPSS Total Score over multiple days between Placebo and Silodosin 8 mg groups. The graph shows greater decrease in score for Silodosin 8 mg over time, with data points plotted at days 3.5, 7, 14, 28, and 94. Statistical significance markers are included.*

FDA Label Image

555 (Silodosin Fig 5)

A line graph comparing the change from baseline in Qmax (mL/sec) over time (days) between Silodosin 8 mg and placebo. The graph shows measurements at baseline, day 1, 7, 14, 28, and 84. Silodosin 8 mg demonstrates a higher increase in Qmax compared to placebo, with statistically significant differences noted.*

FDA Label Image

Silodosin Figure 4

A line graph comparing change from baseline in Cmax (mL/sec) over days for Silodosin 8 mg versus placebo. The x-axis represents days (Baseline, 1, 7, 14, 28, 84/LOCF), and the y-axis shows change from baseline. The Silodosin 8 mg line shows a higher increase in Cmax compared to placebo throughout the time points, with statistical significance noted (p<0.05).*

FDA Label Image

111 (Silodosin Str 01)

Chemical structure diagram of Silodosin, showing its molecular framework including aromatic rings, amide, ether, and other functional groups. The structure depicts atoms and bonds characteristic of the active pharmaceutical ingredient Silodosin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.